All In Biotech

Free tool

FAERS Monitor: Pyridostigmine Bromide

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217604 or its brand name (Pyridostigmine Bromide, Pyridostigmine Bromide). Reports on generic versions are filed under their own applications.

Reports

1,907

Serious

1,327

70% of reports

Hospitalization

648

Death reported

177

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • myasthenia gravis192
  • fatigue165
  • drug ineffective145
  • dyspnoea145
  • off label use130
  • asthenia121
  • headache115
  • diarrhoea113
  • nausea96
  • malaise90
  • dizziness76
  • fall72
  • muscular weakness68
  • pain66
  • death65

Reports by year received

View as table
YearReports
20049
200516
200618
200719
200845
200947
201037
201153
201245
201315
201424
201550
201685
201780
2018104
201978
2020128
2021128
2022109
2023177
2024240
2025241
2026158

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,252 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myasthenia gravisSignal192268.5234.449,719
muscular weaknessSignal686.65.2319
astheniaSignal1213.63.0223
dyspnoeaSignal1452.82.4174
fallSignal722.41.958
fatigueSignal1652.32.0130
malaiseSignal902.31.964
headacheSignal1152.01.760
diarrhoea1131.91.651
dizziness761.71.321
off label use1301.61.433
nausea961.31.18
drug ineffective1451.21.06
pain661.20.92
death650.80.72

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.